Sperm-associated antigen 1 (SPAG1) was recently identified in a rare form of infertility where anti-SPAG1 antibodies derived from the serum of an infertile woman were reported to cause sperm agglutination. Except for its expression and potential role in spermatogenesis, the function of SPAG1 is completely unknown. The unexpected finding of high levels of SPAG1 expression in pancreatic adenocarcinoma compared to normal pancreatic tissue in our previous cDNA array experiments prompted us to look in more detail at the expression and role of this gene in a panel of normal and malignant human tissues as well as in a larger series of pancreatic cancer specimens. We have generated an SPAG1-specific monoclonal antibody and showed high levels of SPAG1 protein in testis and in a large proportion of pancreatic ductal adenocarcinomas (PDAC). In the latter, SPAG1 expression was predominantly cytoplasmic and confined to malignant cells. Furthermore, the extent and intensity of SPAG1 expression was shown to be associated with stage and tumour nodal status, while analysis of precursor lesions, pancreatic intraepithelial neoplasias (PanINs), demonstrated its increased immunoreactivity with increasing PanIN grade, suggesting that SPAG1 is a novel marker of PDAC progression. Immunocytochemical analysis demonstrated colocalization of SPAG1 with microtubules, and their association was confirmed by co-immunoprecipitation; subsequent motility assays further substantiated a potential role of SPAG1 in cancer cell motility. Combined with the finding of its early expression in PDAC development, our data suggest that SPAG1 could contribute to the early spread and poor prognosis of pancreatic adenocarcinoma.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) represents one of the most aggressive and lethal malignant diseases known in humans. It is highly prevalent throughout the industrialised world, and is the fourth leading cause of cancer-related deaths in the United States with up to 30 300 newly diagnosed cases each year (Jemal et al., 2002) . The lack of early clinical symptoms and markers, as well as the high potential of pancreatic cancer cells to form distant metastases, represent hallmark features of PDAC that result in a very low rate of curative resections. In order to improve the poor prognosis of pancreatic cancer patients, new approaches for early diagnosis and therapy are required. To accomplish this, we need a better understanding of the complex molecular events involved in the progression of this malignancy.
One highly productive and informative tool for exploring differential gene expression between healthy and tumour specimens is large scale expression profiling. We and others have recently undertaken such analyses of normal pancreas and pancreatic adenocarcinoma (Crnogorac-Jurcevic et al., 2003; Logsdon et al., 2003; Hustinx et al., 2004; Grutzmann et al., 2005) and our cDNA array data showed overexpression of spermassociated antigen 1 (SPAG1) in cancer cells (Missiaglia et al., 2004) .
The SPAG1 transcript (accession number: AF311312) is 3818 bp in length and encodes a protein of 926 amino acids. It contains three tetratricopeptide (TPR) motifs, an ATP/GTP-binding site and putative phosphorylation sites for PKC, CK2 and cAMP/cGMP-dependent kinases (Lin et al., 2001) . SPAG1 expression, previously thought to occur only in sperm cells during spermatogenesis (Zhang et al., 1992; Lin et al., 2001) , has not been associated with any cancer type before.
Results

SPAG1 RNA expression
Northern blot analysis was performed on mRNA from testis, normal pancreas, the immortalized normal pancreatic ductal cell line HPDE and 10 pancreatic cancer cell lines. Expression of SPAG1 transcript was detected in testis, HPDE and all pancreatic cancer cell lines. Three different transcript sizes were identified; in addition to the larger transcript, which corresponds to the expected size of SPAG1 (approx. 3.8 kb), two smaller transcripts of 2.4 and 1.7 kb were also noted ( Figure 1) .
During the procedure to clone the full-length SPAG1 transcript, an additional splice variant was identified, in which 207 bp is deleted from exons 11 and 12 resulting in the production of an SPAG1 protein 69 amino acids shorter than the full-length protein (Supplementary Figure 1) .
To confirm upregulation of SPAG1 in clinical specimens, quantitative real-time reverse transcription-polymerase chain reaction (QRT-PCR) was employed. The results demonstrate that the SPAG1 transcript is upregulated in 12 out of 18 pancreatic tumour tissues (67%) (Figure 2a ). Weak SPAG1 expression was noted in one out of nine chronic pancreatitis specimens ( Figure 2b ). Immunohistochemical analysis shows a complete absence of immunoreactivity after neutralization of the antibody with a specific SPA3 peptide. Representative image of one of three different PDAC cases analysed in this way is shown on Figure 3B : A negative control where primary antibody was omitted is shown in (a), while SPAG1 immunoreactivity was evident when both unblocked SPAG1 antibody (b) or antibody blocked with SPA1 (c) and SPA2 peptide (data not shown) were used. A complete lack of immunoreactivity was observed when the antibody was blocked with SPA3 peptide (d). Figure 4 shows Western blot analysis using lysates from eight pancreatic cell lines and brain (negative control). In addition to the full-length 104 kDa band, smaller bands of 95 kDa (representing a protein product of an additional splicing variant), 60 and 35 kDa were detected.
SPAG1 protein expression
The LandMark High Density Normal Tissue MicroArray showed no SPAG1 expression in the pancreas, brain (Figure 5a ), thyroid, lung, heart, lymphoid tissue, spleen, urinary bladder, skeletal muscle and ovary (data not shown), and confirmed strong SPAG1 expression in sperm cells of the testis (Figure 5b ). SPAG1 immunoreactivity was also detected in normal stomach, duodenum, colon, gall bladder and liver, as well as in the kidney (data not shown). The High Density Cancer Tissue MicroArray demonstrated that SPAG1 was expressed in three out of 11 prostate cancers, two out of 12 breast, six out of 11 colonic, one out of nine liver and kidney cancers, four out of 13 ovarian, four out of 11 endometrial and one of 14 laryngeal carcinomas (data not shown).
In order to confirm the overexpression of SPAG1 protein in PDAC samples and to determine if it correlates with any of the clinico-pathological data, we constructed and screened a pancreatic tissue microarray: of scorable cores representing 27 different patients, 25 patients (93%) showed detectable SPAG1 expression, Figure 1 Northern blot analysis of SPAG1 in testis, pancreatic cancer cell lines and normal pancreas. In addition to a full-length transcript (3.8 kb), two additional transcripts of around 1.7 and 2.4 kb were also present. Actin was used as a loading control.
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A Neesse et al which was weak in 34% (9/27 cases) and moderate to strong in 60% (16/27). Duplicate or triplicate cores from the same sample gave the same result in the majority of cases. Representative images are shown on Figure 5c -f. Figure 5c shows ductal epithelial cells in the normal pancreas that were largely negative, as well as stromal 
A Neesse et al compartments that were completely devoid of SPAG1 expression. Figure 5d and e show the representative images of SPAG1 expression in two different PDAC cases. SPAG1 expression was confined to the cytoplasm but occasional membranous staining was also noted. Several tissue sections included perineural invasion and local lymph nodes with metastatic spread; in these, strong SPAG1 immunoreactivity was noticed in the invasive cells. Figure 5f illustrates such staining in the metastatic cluster found in the regional lymph node.
Using the w 2 method, a positive and statistically significant association between the extent of SPAG1 expression and tumour stage and extent and nodal status was found; in addition, moderate and strong immunoreactivity (total score >4) was associated with the advanced tumour stages (T3 and T4). No association was observed between SPAG1 immunoreactivity and survival using both univariate and multivariate analysis. The factors associated with survival were tumour size (in both analyses), and there was a borderline association for completeness of excision in univariate analysis only.
The finding of SPAG1 expression in HPDE, which is a 'normal' ductal cell line immortalized with HPV E6 and E7 genes, prompted us to analyse PDAC precursor lesions. The second, independent set of paraffin blocks included pancreatic intraepithelial neoplasia (PanIN) lesions and showed that SPAG1 is expressed in 2/39 (5%) of PanIN1a, 6/26 (23%) 
Localization studies of SPAG1
Immunocytochemical analysis using two pancreatic cancer cell lines, Panc1 and IMIM-PC2, suggested potential colocalization of SPAG1 with tubulin. To investigate this, further additional experiments were undertaken on both sperm and cancer cell lines. In sperm, SPAG1 was localized predominantly in the neck and midpiece, whereas in pancreatic cancer cell lines it was perinuclear and distributed throughout the cytoplasm. This is illustrated in Figure 7 with expression of SPAG1 and tubulin in sperm (a-d) and Panc1 (e-h). In both specimens, a colocalization of SPAG1 with tubulin was noted (d, h). However, colocalization of SPAG1 and actin was not detected in cell lines (Supplementary Figure 2) .
Colocalization of SPAG1 and tubulin prompted us to investigate if they could interact in vivo using co-immunoprecipitation; this is confirmed in Figure 8a and b. After immunoprecipitation with tubulin and SPAG1 antibodies, SPAG1 could be detected using both SPAG1 antibody (lanes 2 and 3) and tubulin antibody (lanes 6 and 7). In panel a, nonspecific signals of approximately 50 and 28 kDa correspond to co-eluted heavy and light immunoglobulin chains, respectively; in panel b only light chain is detected as we used a light chain-specific secondary antibody to avoid the interference of heavy chain with 55 kDa tubulin signal. Furthermore, the 104 kDa band was excised from lanes 2 and 3 from a gel run in parallel, trypsin digested and shown by mass spectrometry to correspond to SPAG1 (Mascot Daemon search identified four SPAG1 peptides that in combination resulted in a probability-based Mowse score of 52) (data not shown).
Functional implications of SPAG1 downregulation
In order to explore a role of SPAG1 in cell motility, we intended to express SPAG1 in non-expressing cell lines and block its expression using the siRNA approach. However, the former was hampered by the fact that all cancer cell lines analysed (both pancreatic and nonpancreatic) expressed substantial amounts of endogenous SPAG1. In addition, as the majority of pancreatic cancer cell lines, including IMIMPC2 show very low efficiency of transfection, both wound healing and migration assays were performed using only the Panc1 cell line.
Different concentrations of siRNAs were tested over the period of 5 days, and the most effective blocking of full-length SPAG1 expression was obtained with 100 nM of siRNA after 48 h (Figure 9a ), although there was always some residual expression of the 35 kDa and occasionally of 60 kDa isoform; these conditions were used in all subsequent cellular motility experiments. Figure 9b shows the results of the transwell migration assay: representative images show the number of cells that migrated through 8 mm pores following treatment with control (upper panel) and SPAG1 siRNA (lower panel), respectively. The number of untreated Panc1 cells that migrated (data not shown) was comparable to the Panc1 cells treated with control siRNA. The histogram in Figure 9c shows that a significantly lower number of cells passed through the filter when the cells were treated with SPAG1 siRNA, suggesting that the migration of Panc1 cells was severely impaired following the reduction of SPAG1 expression. Figure 9d shows the decreased motility of siRNA-treated Panc1 cells in a wound-healing assay. The closing of the wound in SPAG1 siRNA-treated cells was not complete even after 48 h, while cells treated with control siRNA as well as untreated Panc1 cells (data not shown) successfully closed the entire wound. The graph in panel e shows the plotted results of all the replicated experiments, that is, how well the wound was closed after 24 and 48 h. The images were magnified Â 400, so that the values could be more accurately measured (in centimetres).
Enzyme-linked immunosorbent assay
As SPAG1 is immunogenic and leads to infertility in women, we have tried to establish if there is an immune response in patients with pancreatic adenocarcinoma. Enzyme-linked immunosorbent (ELISA) assays were performed on 35 PDAC serum samples and 12 healthy samples; however, there was no evidence of increased anti-SPAG1 antibody levels in any of the patient's serum samples (data not shown), which indicates the lack of a humoral immune response to SPAG1 in PDAC patients.
Discussion
SPAG1 was first described in 1992, when Zhang et al. (1992) isolated a 2.4 kb cDNA protein by screening a human testis lgt11 cDNA library with serum obtained 
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A Neesse et al from an infertile woman. The full-length cDNA of SPAG1, which is 3.8 kb long was described by Lin et al. (2001) . Our Northern blot analysis identified at least three different transcripts of around 3.8, 2.4 and 1.7 kb, whereas Western blot analysis showed four different bands in the majority of lysates tested: 104 kDa, Figure 7 Immunocytochemical analysis of SPAG1 and tubulin in sperm (a-d) and in Panc1 pancreatic cancer cell line (e-h). DAPI shows nuclear reactivity (a, e); SPAG1 staining (b, f); tubulin alone (c, g); colocalization of SPAG1 and tubulin (d, h).
A Neesse et al corresponding to the full-length cDNA clone of 3.8 kb, 96 kDa, which is probably encoded by a new splice variant that we have described here, a band of approximately 60 kDa which potentially corresponds to a band of around 55 kDa expressed in testis as described previously (Lin et al., 2001) , and an additional 35 kDa isoform. As not all cell lines analysed express all isoforms, it is not clear at present if these bands are different SPAG1 isoforms, processed peptides or are present due to the instability of the large SPAG1 protein, and therefore warrants further investigation. The involvement of SPAG1 upregulation in early pancreatic cancer and its progression is intriguing. Several mechanisms have been suggested as possible causes of an aberrant gametogenesis gene expression programme in carcinomas, one of which is genome-wide demethylation. This epigenetic re-programming due to alterations in DNA methylation status occurs in both gametogenesis and embryogenesis, and is also recognized as one of the driving forces of tumorigenesis in somatic cells (Feinberg and Tycko, 2004; Simpson et al., 2005) . However, based on our recent experiments on pancreatic cancer cell lines treated with 5-aza-2 0 deoxycytidine (Missiaglia et al., 2005) , where gene expression profiling was performed using the same platform as in experiments where SPAG1 was found to be upregulated in PDAC samples, SPAG1 did not appear to be influenced by methylation status. An alternative explanation, recently proposed by Old (2001) , suggests that the mutation (either direct or indirect) in an as yet unidentified master switch(es) could trigger a common gametogenic/tumourigenic programme, but this hypothesis still remains to be proven experimentally. The mechanism for SPAG1 upregulation in pancreatic carcinoma therefore still remains to be determined.
Cell motility denotes a shared biological function between sperm and cancer cells and represents a key event in the multistep process of invasion. It requires complex and dynamic interaction between actin and microtubule cytoskeleton (Small et al., 2002; Vasiliev, 2004) . A number of different proteins have already been directly or indirectly implicated in the motility of pancreatic cancer cells, such as integrins and tetraspanins (Gesierich et al., 2005) , cadherin/catenin and Rhofamily GTPases (Taniuchi et al., 2005) , a homeodomain transcriptional regulator CUTL1 (Michl et al., 2005) ; the role of Ras-Raf-MEK-ERK signalling cascades was also highlighted (Giehl et al., 2000; Sawai et al., 2005) . The molecular mechanisms through which SPAG1 exerts its effect on cell motility, as well as the significance of its interaction with tubulin need to be investigated further. 8) . Lanes 1 and 5 show control reactions using mouse IgG; lanes 2 and 6 represent IP with tubulin antibody, whereas lanes 3 and 7 demonstrate IP with SPAG1 antibody. Lanes 4 and 8 show control lysates. SPAG1 was detected using anti-SPAG1 antibody (1 mg/ml) and tubulin with 1:1000 anti-tubulin antibody (Sigma-Aldrich, St Louis, MO, USA). SPAG1 primary antibody was detected using 1:2000 dilution of anti-mouse HRP-conjugated secondary antibody (Autogen Bioclear); for tubulin, anti-mouse light chain (BD Biosciences) was used to avoid the interference with the heavy chain. Both were visualized using ECL Western blotting detection reagents (Amersham Biosciences, Buckinghamshire, UK). Filled arrowheads denote SPAG1, whereas tubulin is indicated by a star sign.
As the SPAG1 transcript was previously reported to be expressed exclusively in testis (Zhang et al., 1999) , its protein product is immunogenic and is re-expressed in cancer, this would suggest that SPAG1 could be a novel CT antigen. By the original, strict definition, CT antigens should be normally expressed only in gametes and trophoblasts and aberrantly expressed in a wide range of human cancers; they should be immunogenic, affected by global hypomethylation and map to chromosome X (Old, 2001; Simpson et al., 2005) . SPAG1 does not appear to fulfil the majority of these requirements: our protein data suggest that the expression of SPAG1 is not limited to testis, but is also present throughout the gastrointestinal tract as well as in normal kidney. It is expressed in several malignancies, although at higher prevalence only in pancreatic cancer, but it does not appear to be immunogenic in pancreatic cancer patients (although the presence of cellular immunity needs to be excluded); it is not affected by changes in methylation status, and it is localized on 8q22.2.
However, in a recent study of 89 distinct CT transcripts that belong to 44 CT gene families, less than half of 43 well-studied CT genes were testis-restricted, with five of them being ubiquitously expressed; only 14/ 29 testis/tissue-restricted CT gene families were actually immunogenic, and members of only 22 CT families are located on X chromosomes (Scanlan et al., 2004) . All the remaining members are usually referred to as either CTA -'Cancer/Testis Associated' (Kalejs and Erenpreisa, 2005) or as 'differentially expressed CT genes', as the bulk of them were discovered in large scale gene . The summary of this data presented as number of migrating cells is shown on (c); the difference in migration between control siRNA and SPAG1 siRNA-treated cells was statistically significant (Po0.05). Wound-healing assay (d) shows that closing of the wound in SPAG1 siRNA-treated cells was not complete even after 48 h, whereas cells treated with the control siRNA successfully closed the entire wound. The wound closure images (400 Â ) were taken at 24 and 48 h intervals and the sizes of the wounds were measured in centimetres (e). The cells treated with control siRNA closed the wound completely after 48 h. expression profiling experiments (Scanlan et al., 2004) , and SPAG1 would probably fit well within this category.
Pancreatic CT genes are among the least studied; the latest report of Kubuschok et al. (2004) shows that out of 10 different CT genes analysed, only HOM-TES-14/ SCP-1 and GAGE were expressed in a significant proportion of pancreatic tumour cases (48 and 21%, respectively), SCP-1 (synaptonemal complex protein) is expressed in almost 50% of PDAC specimens (Tureci et al., 1998) , whereas D40/CT29 was found expressed in not more than 27% of PDACs (Takimoto et al., 2002) . Except for SCP-1, which plays an important role in the alignment of the two homologous chromosomes, in promoting crossing-over events and ensuring chromosome segregation in meiosis (Tureci et al., 1998) , the function of the remaining CT genes is completely unknown.
One of the major interests in CT antigens stems from their potential use in cancer vaccines, and several of them have been used in polyvalent vaccine trials with variable success Sigalotti et al., 2002) . Although the lack of humoral immunity in PDAC patients and the expression of SPAG1 in several normal tissues would probably hamper a similar utility, further studies would need to be undertaken in order to completely exclude the validity of SPAG1 in such an immunotherapeutic approach.
In summary, our data show that SPAG1, a gene involved in spermatogenesis, is expressed in early PDAC development and could potentially be used both as an early diagnostic and a novel progression marker. Moreover, the involvement of SPAG1 in cellular motility could contribute to early cancer spread and the consequent and almost invariable poor prognosis of patients with pancreatic adenocarcinoma.
Material and Methods
Tissues and cell lines
Frozen tissues from normal pancreas, chronic pancreatitis (CP) and pancreatic cancers were obtained from the Human Biomaterials Resource Centre (HBRC), Department of Histopathology, Charing Cross Hospital, London, UK. A total of 18 frozen PDAC, nine CP tissues and a pool of four histologically normal tissues (two donor pancreata and two operative specimens for ampullary tumours sampled at distance from the malignancy) were utilized in QRT-PCR analysis. For immunohistochemistry, two sets of paraffin blocks were used: a first panel from the archives of the Department of Histopathology at Royal London Hospital comprised 39 individual PDAC with full clinico-pathological information (including age, gender, grade, stage, tumour size, resection margin, date of diagnosis, surgery and survival), and were used for construction of the tissue microarray. In total, 98 tissue cores (each 1.2 mm in diameter) were arrayed; in addition to 80 PDAC cores, 10 histologically normal cores adjacent to cancer, two completely normal pancreatic cores and six control cores (duodenum, muscle, ampullary cancer) were also included in the array. A second set of 50 paraffin blocks comprising normal, PanIN and PDAC samples was from the University of Kiel, Germany. Serum samples were kindly provided by Professor Holger Kalthoff, University of Kiel, Germany. All the specimens were obtained with full ethical approval from the host institutions.
A panel of 10 pancreatic cancer cell lines was used: Panc1, A818-4, HPAF-II, MiaPaCa-2, Suit-2, IMIM-PC2, Aspc-1, FA6, MDAPanc3 and T3M4. All cell lines were obtained from Cancer Research UK Cell Services and cultured in E4 medium (Cancer Research UK Media Production, Clare Hall, Middlesex, UK) supplemented with 10% foetal calf serum (PAA Laboratories, GmbH, Germany). The HPDE cell line was a kind gift from Dr Ming-Sound Tsao, University of Toronto, Canada and was grown in keratinocyte medium as described (Furukawa et al., 1996) . Testis RNA was obtained from Ambion Inc. (Austen, TX, USA). Sperm samples were donated by a healthy male volunteer from our research group.
Northern Blot analysis
Total RNA was extracted with TRIZOL reagent (Gibco-BRL, Life Technologies Inc., Frederick, MA, USA) according to the manufacturer's protocol. Messenger RNA was isolated from 75 mg of total RNA using Dynabeads from Dynal Biotech Ltd. (Oslo, Norway), following the supplied protocol. An aliquot of 3 mg of mRNA from each sample was fractionated in 1% agarose gel containing 6% formaldehyde in 3-(N-morpholino) propanesulfonic acid (MOPS) buffer for 4-5 h, transferred to Hybond-N þ membrane (GE Healthcare UK Ltd., Little Chalfont, England) and crosslinked by ultraviolet (UV) illumination. The SPAG1 probe was prepared from an agarose gel-purified PCR product of 330 bp (PCR primers: forward 5 0 GCTAGCTGATGGGAACGTGAA 3 0 , reverse 5 0 GGCTT GGCTATC GGAAGTTTC 3 0 and PCR conditions: 941C 2 min one cycle, 941C 20 s and 561C 20 s for 30 cycles, 721C for 30 s, final extension 10 min at 721C). The primer pairs for the actin probe were: forward 5 0 ATCTGGCACCACACCTTC TACAATGAGCTGCG 3 0 ; reverse 5 0 CGTCATACTCC TGCTTGCTGATCCACATCTGC 3 0 , which amplify 838 bp fragment (PCR conditions: 951C 1 min one cycle, 33 cycles at 951C 1 min, 551C 1 min, and 721C for 1 min before a final extension at 721C for 10 min). The gel purification was performed using Gel extaction kit (Qiagen Ltd). 32 P radioactive probe labelling was performed according to the Random Primed DNA Labelling protocol (Boehringer Mannheim). Hybridization was performed with ExpressHyb Hybridization solution (Takara Bio Europe S.A.S, Saint-Germain-en-Laye, France) at 651C followed by post-hybridization washes as instructed in the manufacturer's protocol. The hybridized membrane was exposed to a Phosphorstorage screen and scanned in a PhosphorImager (Molecular Dynamics, Sunnyvale, CA, USA). The same blot was stripped and rehybridized using actin probe in the same manner.
QRT-PCR cDNA was synthesized from 1 mg of total RNA using random primers and the Multiscribet Reverse Transcription kit (Applied Biosystems, Warrington, Cheshire, UK). The primers used to amplify a 75 bp amplicon were: forward 5 0 AAATTG AGATTCAAGAGGTGAATGAA 3 0 ; reverse 5 0 GGCAT CCCGTGGAGACC 3 0 . Reactions containing 10 ng cDNA, SYBR Green sequence detection reagents (Applied Biosystems, Warrington, Cheshire, UK) and primers were assayed on an ABI7700 sequence detection system (Applied Biosystems). The accumulation of PCR products was measured in real time as the increase in SYBR Green Fluorescence, and the data were analysed using the Sequence Detector program v1.9.1 (Applied Biosystems). All the assays were performed in triplicate and normalized with 18S internal control.
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Quantitative gene expression in tumour samples was compared to the average value of pooled normal samples arbitrarily set at 1.
Cloning of full-length SPAG1 cDNA
The full-length coding sequence of SPAG1 was obtained by PCR using HumanTestis Marathon-Readyt cDNA as a template and Advantage-GC cDNA Polymerase mix (both from Takara Bio Europe, S.A.S, Saint-Germain-en-Laye, France). The primer sequences used were forward: 5 0 CTGGAGCATGACCACCAAAGATTATCC 3 0 and reverse: 5 0 AAGCTCATACTGCCTTTTTAGGGCCTG 3 0 . Sequencing of all PCR products was performed on 3700 automated capillary sequencer with Big Dye terminator mastermix version 3.1 (Applied Biosystems) and an additional splice variant of 2574 bp was observed. PCR product corresponding to a full-length SPAG1 was cloned into pcDNA3.1/V5-His TOPO TA in frame with the V5-His tag to create pcDNA3.1-SPAG1-V5-His (Invitrogen Life Technologies, Paisley, UK). Panc1 cells were transfected using Fugene 6 transfection reagent according to the manufacturer's protocol (Roche Diagnostics Limited, Lewes, UK).
Antibody generation and test of antibody specificity A polyclonal antibody against the protein product of a partial 0.7 kb coding fragment of SPAG1 was kindly supplied to us by Lin and co-workers. However, it did not show immunoreactivity on formaldehyde-fixed, paraffin-embedded tissue. Therefore, we produced and purified a mouse anti-human SPAG1 monoclonal antibody at the Cancer Research UK Hybridoma Fusion Laboratory. Three different peptides designed to avoid regions with TPR motifs were used for immunization of mice (SPA1: VGKEKYSKRPTKKKTPR DYAE; SPA2: QRGQTPEAGADKRSPRRA; SPA3: KTAP FNKEKERRKIEIQEVNE), but the final monoclonal antibody was SPA3-specific.
In order to test this specificity, both SPAG1 (1 mg/ml) and V5 (1:2000) (Invitrogen Life Technologies) antibodies were used in immunoblotting analysis of full-length transfected SPAG1 clone. In addition, SPAG1 antibody was neutralized with 100-fold of each of the three peptides overnight at 41C and used for immunohistochemical analysis.
Western blot analysis
Immunoblotting was performed on the following pancreatic cell lines: HPDE, Panc1, A818.4, HPAF-II, MiaPaCa-2, Suit-2, IMIM-PC2 and Aspc-1. The brain lysate was obtained from BD Biosciences, UK. Total protein lysate (25 mg) was size-fractioned on 4-12% NuPage gradient Bis-Tris-Gel (Invitrogen, Paisley, UK) and blotted onto a nitrocellulose membrane (Milipore, Bedford, USA) for 45 min at 20 V. For immunodetection, the blots were incubated for 45-60 min at room temperature with SPAG1 antibody (1 mg/ml) followed by 1 h incubation with horseradish peroxidase (HRP)-conjugated secondary antibody (Santa Cruz Biotechnology, Heidelberg, Germany). Detection of the bound antibody was carried out using ECL Western blotting detection reagents (Amersham Bioscience, UK). Actin antibody was purchased from Santa Cruz Biotechnology, Heidelberg, Germany.
Immunohistochemical analysis
Immunohistochemistry was performed on 4 mm-thick paraffin sections with a 1:200 dilution of SPAG1 antibody (1 mg/ml). Antigen retrieval was performed using Tris Borate EDTA Cell Conditioning buffer (pH ¼ 8) for 48 min at 951C. The DAB Detection Kit was used according to the protocols provided for the Ventana Discoveryt System, Illkirch, France (www.ventanadiscovery.com) . Counterstaining was performed with haematoxylin.
The intensity of immunoreactivity on pancreatic sections was graded on a scale from 0 to 3 and the extent of positive immunoreactivity was scored according to the percentage of stained cells (0 points for no staining, 1 point for less than 20%, 2 points for 20-50% and 3 points for more than 50% of the cells). The total score was expressed as the product of intensity and extent of staining. Negative or weakly positive cases had a score of 0-3 points, moderately positive had a score of 4-6, and strongly positive cases had a final score greater than 6.
In addition to pancreatic samples, two tissue arrays with 280 normal (LandMark High Density Normal Tissue MicroArray) or 280 cancer cores (LandMark High Density Cancer Tissue MicroArray) were used for a comprehensive analysis of SPAG1 expression across a variety of normal and cancer tissues. The High Density Normal and Cancer Tissue Microarray contain tissues from 23 and 24 different organs, respectively. Due to the small core size (0.6 mm), a simple scoring system was used for these arrays: no expression, moderate or strong expression. All the scoring was performed by two specialist pathologists.
Immunofluorescence IMIM-PC2 and Panc1 cells were grown overnight on chamber slides (Lab-Tek; Nalge Nunc Int., Naperville, IL, USA). Following two washes with phosphate buffered saline (PBS) solution A (PBSA), cells were permeabilized in PHEM buffer (60 mM Pipes, 25 mM Hepes, 10 mM ethyleneglycol-bis(-aminoethyl)-N,N,N,N-tetraacetic acid (EGTA), 3 mM MgCl 2 , pH ¼ 6.8) containing 0.5% Triton X-100 for 1 min at room temperature. Cells were then washed three times with PHEM buffer and fixed for 15 min in methanol at À201C. The semen smear was fixed with ethanol. Non-specific binding sites were blocked with 1% bovine serum albumin (BSA) in PBSA for 30 min at room temperature. Subsequently, cells were incubated with mouse anti-SPAG1 antibody 1:100 (10 mg/ml) and rabbit anti-tubulin antibody (Sigma, 1:100) for 1 h at room temperature. After three washes in PBS, the primary antibodies were detected with Alexa Fluor 488 donkey anti-mouse secondary antibody (1:1000 dilution) and Alexa Fluor 555 goat anti-rabbit secondary antibody (1:500 dilution) (both from Molecular Probes, Leiden, The Netherlands). DNA was stained with 4,6-diamidino-2-phenylindole (DAPI, Molecular Probes) at a dilution of 20 mg/ml in phosphate-buffered saline (PBS). After three washes, slides were mounted using Permafluor aqueous mounting medium (Immunotech, Marseille, France).
A series of optical sections were taken with a Zeiss LSM 510 confocal microscope and were projected to single images using LSM software (Zeiss, Jena, Germany). Photomontages were created using Adobe Photoshop 5.1 software (Mountain View, CA, USA).
To visualize the actin filaments Phalloidin-TRITC (Sigma) at a 1:1000 dilution was used. Except for fixing with 4% paraformaldehyde in PBS for 15 min at room temperature, the cells were otherwise processed as described above.
Co-immunoprecipitation of SPAG1 and tubulin
Triplicate experiments were carried out using protein GSepharoset (Amersham Biosciences, Buckinghamshire, UK) according to the manufacturer's protocol. Briefly, IMIMPC2 cell lysates (500 mg of total proteins) were precleared by incubation with 1/10 volume of protein G-Sepharoset for 2 h at 41C, and precleared lysates were incubated overnight at 41C with 5 mg of SPAG1/tubulin antibody or control mouse immunoglobulin G (IgG) (Sigma-Aldrich, St Louis, MO, USA). Protein G-Sepharose was then added for an additional 2 h. Immune complexes were extensively washed, bound proteins eluted with 2 Â sodium dodecyl sulphate (SDS) sample buffer, and were then separated on 4-12% NuPage gradient Bis-Tris-Gel (Invitrogen, Paisley, UK). After transferring onto nitrocellulose membrane, proteins were subjected to standard Western blotting analysis. For the detection of SPAG1, 1 mg/ml of SPAG1 antibody was used, and for the tubulin, a corresponding antibody in 1:1000 dilution was employed (Sigma-Aldrich, St Louis, MO, USA). SPAG1 primary antibody was detected using the 1:2000 dilution of anti-mouse HRP-conjugated secondary antibody (Autogen Bioclear UK Ltd., Calne, UK), whereas for tubulin, antimouse light chain (BD Biosciences) was used to avoid the interference with the heavy chain. Both were visualized using ECL Western blotting detection reagents (GE Healthcare, UK, Little Chalfont, UK).
Mass spectrometry analysis
Protein bands at approximately 104 kDa were visualized by silver staining and excised from 1D SDS-polyacrylamide gel electrophoresis (PAGE) 12% Gels (18 18 cm Â 1 mm) that were run on a BioRad Protean II System, as described previously (Shevchenko et al., 1996) . The bands were subsequently trypsin digested and analysed using mass spectrometry (MS) as described in Cutillas et al. (2004) .
siRNA experiments Panc1 cells were cultured in E4 media with 10% foetal calf serum (FCS, Life Technologies). For transfection, the cells were trypsinized and 2 Â 10 4 cells/per well plated into six-well plates without antibiotics. After 24 h, cells were transfected with Custom Smartpoolt SPAG1 siRNA (Dharmacon) by using DharmaFECTt siRNA Transfection reagent 1 according to the manufacturer's instructions. The optimal siRNA concentration was 100 nM, and the blocking was monitored for 5 days. For control experiments, Qiagen Control siRNA (Qiagen House, Fleming way, Crawley,West Sussex, UK) was used under the same conditions.
Motility and wound healing assays
After incubation for 48 h with only media or with control and SPAG1 siRNA, the cells were removed by trypsinization, counted and plated at the concentration of 1 Â 10 5 cells/mL in six-well plates. After overnight incubation, the cell monolayer was scratched with a 200 mL pipette tip. Photographs (magnification Â 400) were taken immediately (time zero), 24 and 48 h post-wounding and then printed, so that the distance of migrated cells spanning the wound could be measured more accurately. Within each assay, the experiments were performed in triplicate, and the whole assay was repeated four times.
Motility assays were performed in 24-well format cell culture inserts with 8 mm pores (BIOCOAT Cell Environments, BD Biosciences, Oxford, UK). After 48 h of transfection with control or SPAG1 siRNA, cells were harvested and plated with incomplete E4 medium onto the top of the culture inserts at 1 Â 10 4 cells per insert in a volume of 0.5 ml. The lower chamber contained 0.75 ml complete E4 medium. The plates were incubated at 371C, 5% CO 2 for 18 h. Non-invading cells were removed with a cotton swab soaked in medium. Cells that had moved through the pores onto the lower surface of the filters were fixed and stained using 3% Giemsa blue (Sigma-Aldrich, St Louis, MO, USA), and the number of cells covering the entire filter was counted on an Olympus CX41 microscope at Â 100 magnification. Each experiment was performed in duplicate and the whole assay was performed three times.
ELISA assays SPA3 peptide was conjugated to BSA and purified with the Imject Activated Immunogen Conjugation kit (Pierce) according to the manufacturer's procedure.
Nunc-Immunot 96-well ELISA plates with MaxiSorpt surface (Nalgene Nunc International, Denmark) were coated with 1 mg of conjugated peptide in PBS overnight at 41C. Plates were washed with PBS/0.05% Tween and blocked with PBS/ 0.05% Tween with 1% BSA. Plates were then washed and incubated for 1 h with 1 mg of serum samples. After two washes, the primary antibodies were detected using Goat antiHuman IgG Horseradish Peroxidase Conjugate (Bio-Rad Laboratories Ltd., Hemel Hempstead, UK). The peroxidase was detected by OPD substrate (Sigma-Aldridge) and the absorbances were recorded at 490 nm.
Statistical analysis
In order to compare SPAG1 positivity with pathological features, Fisher's exact and Pearson's w 2 test were used. For univariate analysis, Mann-Whitney test was employed. To evaluate the putative effect of SPAG1 expression on patients' survival, log-rank test was performed, and survival curves were plotted using Kaplan-Meier method. The features associated with SPAG1 immunoreactivity and survival were also entered into multivariate Cox regression analysis models.
For w 2 tables and univariate survival analyses, dichotomized results were used (SPAG1 extent equal/>80% or o80%; SPAG1 score o4 or equal/>4). For multivariate analyses, continuous variables were used where appropriate, otherwise dichotomized.
All the statistical tests were performed within the SPSS package (Statistical Package for the Social Sciences) version 11.0 (Chicago, IL, USA). The level of significance used was Po0.05.
Abbreviations
SPAG1, sperm-associated antigen 1; PanIN, pancreatic intraepithelial neoplasia; PDAC, pancreatic ductal adenocarcinoma; CP, chronic pancreatitis; TPR motif, tetratricopeptide motif; QRT-PCR, quantitative real-time reverse transcription-polymerase chain reaction; ESI, electrospray ionization, CT genes' cancer/testis genes; IHC, immunohistochemistry.
